Back to top

Krystal Biotech sees global VYJUVEK expansion and expects Q3 revenue dip before renewed growth

Krystal Biotech sees global VYJUVEK expansion and expects Q3 revenue dip before renewed growth

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Krystal Biotech, Inc. (KRYS)